Dog Drug Shows Promise for Human Health Crisis

Whipworm Infection: A Global Health Challenge

On the small Tanzanian island of Pemba, a groundbreaking experiment is underway that could offer a lifeline to hundreds of millions worldwide. Researchers are testing a drug, originally developed for pets, to combat whipworm infections, a debilitating parasitic disease often termed a “poverty disease.” These infections, caused by the whipworm Trichuris trichiura, affect an estimated half a billion people globally, leading to symptoms ranging from bloody diarrhea and nausea to stunted growth in children. The transmission often occurs in areas with poor sanitation, where open defecation and contaminated soil allow eggs to be ingested.

From Pet Medicine to Human Hope: The Story of Emadepsid

The drug at the center of this trial is called Emadepsid. While it has been a safe and effective treatment for cats and dogs since 2006, its potential for human use remained untapped for two decades. Dr. Jennifer Kaiser, leading the research at the Swiss Tropical and Public Health Institute, has made it her mission to bring this drug to humans. “Neglected tropical diseases mostly have no market because it affects the poorest of the poor populations,” Dr. Kaiser explained. “So, we have to be quite creative when it comes to discovering and developing a new drug.” This often means drawing inspiration from veterinary medicine.

Nature’s Inspiration: The Japanese Camellia

The journey of Emadepsid began with a unique source of inspiration: a Japanese plant. Akim Harder, the scientist who developed the drug for the pharmaceutical giant Bayer, was tasked in the 1990s with creating a medicine that could overcome drug resistance in worms. His search led him to the Camellia japonica plant. A fungus found in its leaves produces a chemical compound that protects the plant from soil nematodes (tiny worms). “Basically, the substance helps the plant protect itself from all sorts of tiny worms,” Harder stated. Recognizing its potential, Harder collaborated with Japanese chemists to synthesize this compound into a drug, Emadepsid, which proved highly effective against a broad spectrum of parasitic worms in animal models.

Overcoming Market Barriers for Human Treatment

Despite its proven efficacy and a ready market in pet care, Bayer initially focused on the lucrative pet market for Emadepsid. “That’s a very very difficult topic because the primary goal is to make money,” a researcher noted, highlighting the economic realities of drug development. “The market for pets is very big. So buyer was able to make money there. But antiparasitic drugs for humans basically have no market.” Pharmaceutical companies often rely on donations for such treatments, offering little return on investment. However, several factors have shifted the landscape:

• Increased Funding: Philanthropic initiatives focused on neglected tropical diseases have provided crucial financial backing.
• Regulatory Incentives: The U.S. Food and Drug Administration (FDA) offers financial rewards to encourage the development of treatments for these infections.
• Growing Resistance: Parasitic worms are developing resistance to existing drugs, increasing the urgency for new medications.

Persistence Pays Off: From Pharmacy to Clinical Trials

By 2018, the conditions were finally favorable for Emadepsid’s human development. However, Bayer was initially hesitant to release the drug for human trials. Undeterred, Dr. Kaiser and her team took a resourceful approach. “The quickest way was to obtain um dogs and cats medicine from the pharmacy and I had a chemist in the group and she quickly extracted the active ingredient and then we could run our essays,” she recalled. These promising early results convinced Bayer to collaborate, assisting with drug formulation, data management, and the approval process.

Pemba Island Trials and Positive Patient Feedback

Pemba Island, with its high prevalence of whipworm infections, was a natural choice for the clinical trials. “It’s really a dream working in this environment,” Dr. Kaiser shared, reflecting on her 15 years of research on the island. The initial trials yielded encouraging results, with the drug successfully eliminating whipworm eggs in the stool samples of nearly all participants. While some participants reported minor, temporary side effects like blurred vision, the overall feedback was positive. One participant shared, “Before taking the medicine, I had a bit of a problem with loss of appetite and often felt dizzy. But after taking the medication, I felt much better… I don’t have problems and the medicine hasn’t caused serious side effects.”

The Road Ahead: Approval and Global Impact

A final trial is now underway in the Philippines before Emadepsid can be submitted for registration. If approved, Bayer plans to market the drug at a “social price,” a low cost that covers production expenses. This approach represents a compromise, ensuring accessibility while acknowledging the company’s investment. There is a possibility that approval could come within this decade, marking a significant breakthrough in the fight against neglected tropical diseases. “It’s probably the dream of every scientist,” reflected a researcher on the potential impact. “But it’s worth remembering the drug that could improve hundreds of millions of lives was there 20 years ago. What was missing wasn’t the science. It was financial incentive.”

Source: This dog medication could change human lives | DW News (YouTube)